Savara Pharmaceuticals

Executive Summary

Savara Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for rare respiratory diseases, with its lead candidate, an inhaled formulation of granulocyte-macrophage colony-stimulating factor (GM-CSF), targeting autoimmune pulmonary alveolar proteinosis (aPAP). Currently in Phase 3 trials, Savara leverages orphan drug designation and pulmonary expertise to address significant unmet medical needs. The company is privately held with a valuation of approximately $1.14 billion, reflecting strong investor confidence in the potential of its pipeline. With no approved therapies for aPAP, successful development could capture a substantial market opportunity. Savara’s focused strategy and advanced clinical stage position it for potential regulatory milestones that could transform the treatment landscape for this rare disease.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 top-line data readout for inhaled GM-CSF in aPAP65% success
• Q2 2026FDA pre-NDA meeting or breakthrough therapy designation80% success
• Q3 2026Strategic partnership or licensing deal for ex-US commercialization70% success